Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 7/20 | 0.97 |
| ▸ | TSHR | P16473 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.46 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23145504 | 1.00 | PTGS2 (0.97) | PTGS2TSHRALDH1A1LMNAKDM4E | |
| SCHEMBL5605205 | 0.99 | PTGS2 (1.00) | PTGS2TSHRALDH1A1LMNAKDM4E | |
| SCHEMBL10121464 | 0.93 | PTGS2 (0.85) | PTGS2TSHRALDH1A1LMNAKDM4E | |
| SCHEMBL15889887 | 0.91 | PTGS2 (0.85) | PTGS2TSHRALDH1A1LMNAKDM4E | |
| SCHEMBL554806 | 0.91 | PTGS2 (0.84) | PTGS2TSHRALDH1A1LMNAKDM4E | |
| SCHEMBL10121462 | 0.89 | PTGS2 (0.78) | PTGS2TSHRALDH1A1LMNAKDM4E | |
| SCHEMBL3029701 | 0.89 | PTGS2 (0.77) | PTGS2TSHRALDH1A1LMNAKDM4E | |
| SCHEMBL3033273 | 0.89 | PTGS2 (0.77) | PTGS2TSHRALDH1A1LMNAKDM4E | |
| SCHEMBL12715080 | 0.88 | PTGS2 (0.75) | PTGS2TSHRALDH1A1LMNAKDM4E | |
| SCHEMBL9446603 | 0.88 | PTGS2 (0.75) | PTGS2TSHRALDH1A1LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220233501-A1 | THERAPEUTIC COMBINATIONS | SUPERSALUS INC (US) | 2022-07-28 | — | — | US | claimed |
| US-20260115188-A1 | METHODS OF TREATING CENTERAL NERVOUS SYSTEM DISORDERS COMPRISING ADMINISTERING DEUTERATED LUMATEPERONE AND A NITRIC OXIDE DONOR | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-04-30 | — | — | US | disclosed |
| US-12478623-B2 | Methods of treating central nervous system disorders comprising administering lumateperone and a nitric oxide donor | INTRA-CELLULAR THERAPIES, INC. (US) | 2025-11-25 | — | — | US | disclosed |
| WO-2024182375-A1 | COMPOSITIONS COMPRISING NITRIC OXIDE-RELEASING COMPOUNDS FOR TREATING CHOROIDAL VASCULAR DISEASES AND METHODS OF THEIR USE | OPTICGON LLC (US) | 2024-09-06 | — | — | WO | disclosed |
| US-20240285572-A1 | COMPOSITIONS COMPRISING NITRIC OXIDE-RELEASING COMPOUNDS FOR TREATING CHOROIDAL VASCULAR DISEASES AND METHODS OF THEIR USE | OPTICGON LLC | 2024-08-29 | — | — | US | disclosed |
| US-20220362241-A1 | NOVEL METHODS | INTRA-CELLULAR THERAPIES, INC. | 2022-11-17 | — | — | US | disclosed |
| EP-4034119-A1 | NOVEL METHODS | Intra-Cellular Therapies, Inc. (US) | 2022-08-03 | — | — | EP | disclosed |
| US-20220233501-A1 | THERAPEUTIC COMBINATIONS | SUPERSALUS INC (US) | 2022-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220362241-A1 | NOVEL METHODS | HTR2A, HTR2C, HTR2B | PTGS2 331/4885TSHR 382/4885ALDH1A1 752/4885 |
| US-20260115188-A1 | METHODS OF TREATING CENTERAL NERVOUS SYSTEM DISORDERS COMPRISING ADMINISTERING DEUTERATED LUMATEPERONE AND A NITRIC OXIDE DONOR | HTR2C, DRD2, HTR2A | PTGS2 229/4885TSHR 118/4885ALDH1A1 669/4885 |
| US-12478623-B2 | Methods of treating central nervous system disorders comprising administering lumateperone and a nitric oxide donor | HTR2A, HTR2C, HTR5A | PTGS2 171/4885TSHR 450/4885ALDH1A1 436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.